Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators

Hirohisa Okabe, Daisuke Hashimoto, Akira Chikamoto, Morikatsu Yoshida, Katsunobu Taki, Kota Arima, Katsunori Imai, Yoshitaka Tamura, Osamu Ikeda, Takatoshi Ishiko, Hideaki Uchiyama, Toru Ikegami, Norifumi Harimoto, Shinji Itoh, Yo ichi Yamashita, Tomoharu Yoshizumi, Toru Beppu, Yasuyuki Yamashita, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential. Methods: Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed. Results: Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 %), lymph node metastasis (36 vs. 3 %), pathologic capsular invasion (68 vs. 8 %), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 %), and histologic grade 2/3 (41 vs. 0 %). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041). Conclusions: Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.

Original languageEnglish
Pages (from-to)1399-1405
Number of pages7
JournalAnnals of Surgical Oncology
Volume24
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Neuroendocrine Tumors
Tomography
Neoplasms
Neoplasm Metastasis
Neoplasm Staging
Multivariate Analysis
Retrospective Studies
Lymph Nodes
Recurrence
Survival
Liver

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. / Okabe, Hirohisa; Hashimoto, Daisuke; Chikamoto, Akira; Yoshida, Morikatsu; Taki, Katsunobu; Arima, Kota; Imai, Katsunori; Tamura, Yoshitaka; Ikeda, Osamu; Ishiko, Takatoshi; Uchiyama, Hideaki; Ikegami, Toru; Harimoto, Norifumi; Itoh, Shinji; Yamashita, Yo ichi; Yoshizumi, Tomoharu; Beppu, Toru; Yamashita, Yasuyuki; Baba, Hideo; Maehara, Yoshihiko.

In: Annals of Surgical Oncology, Vol. 24, No. 5, 01.05.2017, p. 1399-1405.

Research output: Contribution to journalArticle

Okabe, H, Hashimoto, D, Chikamoto, A, Yoshida, M, Taki, K, Arima, K, Imai, K, Tamura, Y, Ikeda, O, Ishiko, T, Uchiyama, H, Ikegami, T, Harimoto, N, Itoh, S, Yamashita, YI, Yoshizumi, T, Beppu, T, Yamashita, Y, Baba, H & Maehara, Y 2017, 'Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators', Annals of Surgical Oncology, vol. 24, no. 5, pp. 1399-1405. https://doi.org/10.1245/s10434-016-5630-4
Okabe, Hirohisa ; Hashimoto, Daisuke ; Chikamoto, Akira ; Yoshida, Morikatsu ; Taki, Katsunobu ; Arima, Kota ; Imai, Katsunori ; Tamura, Yoshitaka ; Ikeda, Osamu ; Ishiko, Takatoshi ; Uchiyama, Hideaki ; Ikegami, Toru ; Harimoto, Norifumi ; Itoh, Shinji ; Yamashita, Yo ichi ; Yoshizumi, Tomoharu ; Beppu, Toru ; Yamashita, Yasuyuki ; Baba, Hideo ; Maehara, Yoshihiko. / Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. In: Annals of Surgical Oncology. 2017 ; Vol. 24, No. 5. pp. 1399-1405.
@article{16e9e502a3664186a06960277c0ed9f7,
title = "Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators",
abstract = "Background: Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential. Methods: Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed. Results: Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 {\%}), lymph node metastasis (36 vs. 3 {\%}), pathologic capsular invasion (68 vs. 8 {\%}), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 {\%}), and histologic grade 2/3 (41 vs. 0 {\%}). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041). Conclusions: Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.",
author = "Hirohisa Okabe and Daisuke Hashimoto and Akira Chikamoto and Morikatsu Yoshida and Katsunobu Taki and Kota Arima and Katsunori Imai and Yoshitaka Tamura and Osamu Ikeda and Takatoshi Ishiko and Hideaki Uchiyama and Toru Ikegami and Norifumi Harimoto and Shinji Itoh and Yamashita, {Yo ichi} and Tomoharu Yoshizumi and Toru Beppu and Yasuyuki Yamashita and Hideo Baba and Yoshihiko Maehara",
year = "2017",
month = "5",
day = "1",
doi = "10.1245/s10434-016-5630-4",
language = "English",
volume = "24",
pages = "1399--1405",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators

AU - Okabe, Hirohisa

AU - Hashimoto, Daisuke

AU - Chikamoto, Akira

AU - Yoshida, Morikatsu

AU - Taki, Katsunobu

AU - Arima, Kota

AU - Imai, Katsunori

AU - Tamura, Yoshitaka

AU - Ikeda, Osamu

AU - Ishiko, Takatoshi

AU - Uchiyama, Hideaki

AU - Ikegami, Toru

AU - Harimoto, Norifumi

AU - Itoh, Shinji

AU - Yamashita, Yo ichi

AU - Yoshizumi, Tomoharu

AU - Beppu, Toru

AU - Yamashita, Yasuyuki

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential. Methods: Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed. Results: Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 %), lymph node metastasis (36 vs. 3 %), pathologic capsular invasion (68 vs. 8 %), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 %), and histologic grade 2/3 (41 vs. 0 %). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041). Conclusions: Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.

AB - Background: Prognostic indicators of the malignant potential of pancreatic neuroendocrine tumors (PNET) are limited. We assessed tumor shape and enhancement pattern on contrast-enhanced computed tomography as predictors of malignant potential. Methods: Sixty cases of PNET patients undergoing curative surgery from 2001 to 2014 were enrolled onto our retrospective study. Preoperative enhanced CTs were assessed, and criteria defined for regularly shaped and enhancing tumors (group 1), and irregularly shaped and/or enhancing tumors (group 2). The relation of tumor shape and enhancement pattern to outcome was assessed. Results: Interobserver agreement was substantial (kappa = 0.74). Group 2 (n = 24) was significantly correlated with synchronous liver metastasis (23 vs. 0 %), lymph node metastasis (36 vs. 3 %), pathologic capsular invasion (68 vs. 8 %), larger tumor size (30 vs. 12 mm), tumor, node, metastasis classification system (TNM) stage III/IV disease (46 vs. 3 %), and histologic grade 2/3 (41 vs. 0 %). Multivariate analysis revealed that tumor grade 2/3 and group 2 criteria correlated with tumor relapse (hazard ratio 6.5 and 13.6, P = 0.0071 and 0.039, respectively), and that only group 2 criteria were independently correlated with poor overall survival (hazard ratio 5.56e + 9, P = 0.0041). Conclusions: Irregular tumor shape/enhancement on preoperative computed tomography is a negative prognostic factor after curative surgery for PNET.

UR - http://www.scopus.com/inward/record.url?scp=84997703737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997703737&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5630-4

DO - 10.1245/s10434-016-5630-4

M3 - Article

C2 - 27896509

AN - SCOPUS:84997703737

VL - 24

SP - 1399

EP - 1405

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -